How would you propose we incentivize drug companies to spend $1B and 10 years in development&#x2F;time costs (in the oncology space, for instance) if there is no IP to protect that investment?<p>Drug development is hard, expensive, and littered with failure. There isn&#x27;t a simple approach to this problem.